Kamada Ltd.
KMDA
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunizatioā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$6.82
Price-0.87%
-$0.06
1Y
Price
Market Cap
$392.184m
Small
Price/Earnings 3y Avg5y Avg
21.3x
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$169.517m
-
1y CAGR-
3y CAGR-
5y CAGREarnings
$19.011m
-
1y CAGR-
3y CAGR-
5y CAGREPS
$0.34
-
1y CAGR-
3y CAGR-
5y CAGRBook Value
$259.954m
$368.173m
Assets$108.219m
Liabilities$11.415m
DebtDebt to Assets
3.1%
0.3x
Debt to EBITDAFree Cash Flow
$31.589m
-
1y CAGR-
3y CAGR-
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company